Why is Akums Drugs falling/rising?

As of 01-Aug, Akums Drugs & Pharmaceuticals Ltd is currently priced at 511.30, experiencing a decline of 7.45 points, which represents a 1.44% decrease. The stock has been underperforming, with a consecutive fall over the last three days resulting in a total drop of 5.94%. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Despite a recent increase in investor participation, with delivery volume rising by 558.5% against the 5-day average, the stock's performance over the past month shows a significant decline of 10.72%, while the year-to-date return is down by 19.87%. Positive factors include a low debt-to-equity ratio and strong quarterly results, with net sales reaching a record high, but these are overshadowed by concerns over long-term growth, as net sales have only grown at an annual rate of 6.10% over the last five years.
In the broader market context, the stock's short-term performance has been notably worse than the benchmark, with a 1-week return of -3.57% compared to the Sensex's -1.06%. The pharmaceuticals and drugs sector has also seen a decline of 3.26%, indicating a challenging environment for stocks in this industry. While Akums Drugs has shown some positive financial metrics, such as a significant increase in profits, the overall market sentiment and the company's poor long-term growth prospects are contributing to its current downward price movement.